Moderna's Q2 Earnings Imminent: Analysts Revise Forecasts Amid Job Cuts and Sales Decline

Moderna's Q2 earnings are expected on August 1, with a projected quarterly loss of $2.97 per share and revenue of $112.96 million. The company has announced plans to reduce its global workforce by 10% by year-end due to decreasing COVID-19 vaccine sales. Benzinga's most accurate analysts have downgraded or maintained underweight ratings on the stock, with some cutting price targets from $33 to $26.

Moderna, Inc. (MRNA) is set to release its second-quarter earnings results on August 1, with expectations indicating a challenging period ahead. The company is projected to report a quarterly loss of $2.97 per share, a significant decrease from the year-ago loss of $3.33 per share [1]. Revenue is expected to reach $112.96 million, down from $241 million in the same quarter last year.

The financial outlook is compounded by Moderna's decision to reduce its global workforce by approximately 10% by the end of the year, a move attributed to decreasing COVID-19 vaccine sales and market uncertainty [1]. This workforce reduction is part of broader cost-cutting measures aimed at stabilizing the company's financial position.

Analysts have been cautious in their ratings and price targets for Moderna's stock. Jessica Fye of JP Morgan maintained an Underweight rating and cut the price target from $33 to $26 on May 22, 2025 [1]. Cory Kasimov of Evercore ISI Group maintained an In-Line rating and lowered the price target from $50 to $32 on May 2, 2025 [1]. Matthew Harrison of Morgan Stanley kept an Equal-Weight rating but reduced the price target from $39 to $32 on April 9, 2025 [1]. Citigroup's Geoff Meacham initiated coverage with a Neutral rating and a price target of $40 on March 13, 2025 [1]. Argus Research analyst John Eade downgraded the stock from Buy to Hold on December 18, 2024 [1].

Moderna's stock has been volatile, falling 8.1% to close at $29.56 on Thursday, reflecting the market's concern over the company's financial performance and the impact of the workforce reduction [1]. Investors will be closely watching the earnings call for any updates on new product launches and progress in the company's pipeline, as well as any signs of improvement in COVID-19 vaccine demand.

References:
[1] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46785048/moderna-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call